Abstract
This editorial refers to ‘Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices, by D.T. Martin et al ., doi:10.1093/eurheartj/ehv115 Atrial fibrillation (AF) is the most common clinical arrhythmia, which is responsible for at least 15% of all strokes, and is the leading cause of stroke among patients >75 years old.1 Moreover, strokes due to AF are largely avoidable, as the use of oral anticoagulants (OACs),2,3 along with the diagnosis and treatment of hypertension,4 can prevent >65% of all strokes. The results of large cohort studies in pacemaker patients demonstrate that AF is frequently ‘subclinical’ (either asymptomatic or which evades clinical detection),5,6 suggesting that the true burden of AF in patients over the age of 65 years is much greater than previously appreciated. These studies also show that subclinical AF ( Figure 1 ) is associated with up to a 2.5-fold increase in the risk of stroke,5,7 highlighting the importance of recognizing this condition in patients with pacemakers and implantable cardioverter defibrillators (ICDs). Figure 1 Atrial fibrillation detected by a dual-chamber pacemaker. Martin and colleagues now present the results of the IMPACT trial,8 a 2718 patient, prospective randomized trial that evaluated a strategy to diagnose and manage patients with ICD-detected AF, in patients without contraindications to OACs. Although the patient population was broad and simply defined, the intervention studied by the investigators was quite complex. Patients in the intervention arm of …

This publication has 15 references indexed in Scilit: